Common Stock
ARENA PHARMACEUTICALS INC
NASDAQ:ARNA (3/10/2022, 7:10:48 PM)
After market: 99.99 0 (0%)99.99
+0.06 (+0.06%)
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 448 full-time employees. The company went IPO on 2000-07-28. The firm's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
ARENA PHARMACEUTICALS INC
6154 Nancy Ridge Dr
San Diego CALIFORNIA 92121
P: 18584537200.0
CEO: Amit D. Munshi
Employees: 448
Website: http://www.arenapharm.com/
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
Here you can normally see the latest stock twits on ARNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: